Long-term surviving mice from first tumor challenge(90 days after first challenge), but not naïve mice, were resistant to asubsequent rechallenge i.p. with ID8 cells (Figure 1E),indicating that combined anti-PD-1/GITR mAb treatment mounted an antitumor memoryimmune response in mice. Here, TNFRSF18 is linked to neoplasm.